BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 29
• 30
• 31

• Biotech Bay

  SI-BONE, Inc. Garners A Gold MarCom Award For The Patient Advocacy Website

  December 9, 2014

   · 

  5 min read
• Business

  Pharnext Announces The Nomination Of Michel De Rosen, A Pharmaceutical And Biotechnology Industry Leader, To Its Board Of Directors

  December 9, 2014

   · 

  2 min read
• Drug Development

  Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR

  December 9, 2014

   · 

  6 min read
• Genetown

  A More Hygienic Way To Measure For Fever: Introducing The Braun No Touch + Forehead Thermometer

  December 9, 2014

   · 

  4 min read
• Business

  Sanford I. Weill Retires As Chair Of The Weill Cornell Medical College Board Of Overseers After 20 Years Of Transformative Leadership

  December 9, 2014

   · 

  9 min read
• Drug Development

  Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting

  December 9, 2014

   · 

  7 min read
• AngioChem Publishes Data On ANG4043, A Brain-Penetrant Anti-HER2 Monoclonal Antibody For Treatment Of Brain Metastases

  December 9, 2014

   · 

  3 min read
• BioCapital

  17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference To Highlight Industry Financing, Current Policy Trends And The 2015 Market Outlook

  December 9, 2014

   · 

  1 min read
• Drug Development

  Fate Therapeutics Highlights Effects Of Nutrient-Rich Media On Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood

  December 9, 2014

   · 

  6 min read
• Drug Development

  TG Therapeutics, Inc. Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)

  December 9, 2014

   · 

  9 min read